Phase 2 N=180 Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=236 Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
Graft-versus-Host Disease · Immune System Disorders
Primary: GVHD-free Survival — 60; 69; 59; 47 participants
Phase 2 N=279 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Phase 2 N=122 A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
Acute GVHD
Primary: Percentage of Participants With Complete or Partial Response (CR/PR) to Acute GVHD Treatment — 35; 46; 19; 17 Participants
Phase 3 N=34 The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease
Acute Graft Versus Host Disease
Primary: The Percentage of Patients Who Progress Within 28 Days of Initiation of Etanercept Treatment — 29 percentage of patients
Phase 2 N=30 Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
Acute Graft vs Host Disease
Primary: The Number of Participants With Lower Gastrointestinal Acute Graft-Versus-Host-Disease Treatment Response Rate on Day 28 — 19; 8 Participants
Phase 3 N=151 Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Chronic GVHD
Primary: Proportion of Participants With Treatment Success — 33; 35; 33; 37 Participants — p=0.63
Phase 2 N=30 A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
Graft-versus-host-disease · GVHD
Primary: Number of High Risk Patients Who Develop Steroid Refractory GVHD — 6 Participants
Phase 3 N=55 A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
Grade B aGVHD · Grade C aGVHD · Grade D aGVHD
Primary: Overall Response Rate (ORR) at Day 28 Post Initiation of Therapy — 69.1 percentage of participants — p=0.0003
Phase 2 N=50 Pediatric GVHD Low Risk Steroid Taper Trial
Acute Graft vs Host Disease · Allogeneic Bone Marrow Transplantation · Adverse Effects
Primary: Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure — 41 Participants
Phase 2 N=70 Itacitinib for Low Risk GVHD
Low Risk Acute Graft-versus-host Disease · Graft-versus-host-disease · GVHD
Primary: Number of Patients Who Achieve CR or PR by Day 28 of Treatment — 62 Participants
Phase 2 N=76 Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Acute Graft Versus Host Disease
Primary: Number of Participants With Complete Response (CR) — 34 Participants
Phase 3 N=164 Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
Graft Versus Host Disease · Recurrent Adult Acute Lymphoblastic Leukemia
Primary: Mean Cumulative Prednisone Dose (mg/kg) Over 42 Days From the Start of Treatment — 22.2; 27.1; 38.4; 41.3 milligrams per kilogram — p=0.08
Phase 1 N=10 Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Graft Vs Host Disease · Graft-versus-host-disease
Primary: Safety and Tolerability of Belimumab as Prophylaxis of Chronic GvHD in Subjects Following alloHCT as Measured by Number of Participants Who Experience Each Adverse Event…
Phase 3 N=136 Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone
Graft Versus Host Disease (GVHD)
Primary: Overall Response Rate (ORR) to Acute Graft-versus-Host Disease (GVHD) Treatment — 60.0; 45.1 percentage of participants — p=0.034
Phase 2 N=22 Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)
Graft-Versus-Host Disease
Primary: Phase I: Maximum Tolerated Dose (MTD) in Milligrams — 5 MTD of oral LBH589 in milligrams
Phase 2 N=21 Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD
Graft Versus Host Disease
Primary: GVHD-free Survival Rate — 33.3 percentage of patients
Phase 3 N=439 GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease
Graft-versus-host Disease (GVHD)
Primary: Overall Response Rate Based on Center for International Blood and Marrow Transplant Research (CIBMTR) Response Index — 74.0; 66.4 Percentage of Participants — p=0.0782
Phase 2 N=20 Alpha 1 Anti-Trypsin (AAT) in Treating Patients With Acute Graft-Versus-Host Disease GVHD)
Graft-Versus-Host Disease (GVHD) Acute on Chronic
Primary: Number (Percentage) of Patients at Each Dosing Cohort Who Experience no Toxicity and in Whom Graft Versus Host Disease (GVHD) is Stable or Improved — 6; 2; 2 Participants
Phase 3 N=254 Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
GVHD · Adult Acute Myeloid Leukemia · Adult Acute Lymphoid Leukemia
Primary: Number of Participants With First Occurrence of Moderate to Severe Chronic GVHD According to 2005 NIH Criteria as Determined by the Independent Endpoint Committee or…
Phase 2 N=10 Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
Chronic GVHD
Primary: Fraction of Participants With an Overall Response Rate (Complete Response [CR] + Partial Response [PR]) Reported With an 80% Confidence Interval at 6 Months — 0; 0.1667…
Phase 2 N=49 RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
Graft Vs Host Disease · Graft-versus-host-disease · Acute-graft-versus-host Disease
Primary: Grades II-IV aGVHD — 11 Participants
Phase 2 N=30 Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)
GVHD, Chronic
Primary: Overall Response Rate (ORR) — 73.3 percentage of participants
Phase 2 N=36 Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Leukemia, Mast-Cell · Mantle-cell Lymphoma
Primary: Chronic Graft-vs-Host Disease (cGvHD) — 20 percentage of participants
N/A N=37 A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
Graft vs Host Disease
Primary: Number of Participants With the Ability to Successfully Taper Prednisone to a Dose Lower Dose. — 14 Participants
Phase 2 N=46 Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
Graft-versus-host Disease
Primary: Percentage of Participants With Grade II-IV Acute GvHD by Day +120 — 17.4 Percentage of participants
Phase 2 N=20 Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
Sclerotic Graft Versus Host Disease · Imatinib Mesylate
Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline
Phase 2 N=25 Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
Chronic Graft-versus-host Disease
Primary: Rate of Complete Response of cGVHD to Treatment. — 84 percentage of patients — p=<0.5
Phase 2 N=313 Abatacept as GVHD Prophylaxis Phase 2
Graft vs Host Disease · Malignancy
Primary: Percentage of Participants With Cumulative Incidence of Severe aGVHD at Day +100 Post-transplant — 6.8; 14.8; 2.2; 30.2 percentage of participants
Phase 3 N=6 Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
Acute Lymphoblastic Leukemia · Acute Myelocytic Leukemia · Chronic Myelocytic Leukemia
Primary: Determining Whether the Hepatic Adverse Event-free (NCI Grades II-IV) Survival at Day 42 After an HLA-matched Transplant for Hematologic Malignancy Can be Improved by…